Entera Bio Ltd.

ENTX Healthcare Biotechnology

Entera Bio Ltd.’s revenue for fiscal 2025 (year ended December 2025) was $42,000.00, down 76.8% from fiscal 2024. In the quarter to June 2026, revenue grew 200.0%, EPS fell 133.3% and free cash flow fell 108.9%, each against the same quarter a year earlier. Insiders bought in the last twelve months.

2.51 0.14 −5.28%
Market cap
$460.7M
P/E
0.0×
Fwd P/E
−3.5×
Dividend yield
—
F-score
n/a
Altman Z
6.22
Beneish M
n/a
Dividend safety
n/a
Older periods Sep '25 Dec '25 Mar '26 Jun '26
P/E ratio

+8 more quarters

— — — —
EV/Sales
— — — —
EV/FCF
— — — —
Current Ratio
10.83 6.94 7.93 8.98
Net Debt/EBITDA
5.11 4.90 3.38 4.05
Debt/Equity
0.00 0.00 0.00 0.00
Free Cash Flow Yield
— — — —
Free Cash Flow per Share
(0.05) (0.04) (0.06) (0.07)
Book value per Share
0.32 0.28 0.22 0.14
Free Cash Flow
(2.54) (1.86) (3.09) (3.47)
EV/EBIT
— — — —
Other line items

Show all line items

Columns are period end dates